The delivery of medication from the AEROECLIPSE* II BAN* to the lungs was not affected by the incorporation of the Aerobika* OPEP device. Aerosol deposition within the lung was unaltered by the addition of the OPEP device as evidenced by the near identical percentage of the dose being deposited in both the peripheral and central airways.
BAN+OPEP therapy could offer the clinician the opportunity for combined treatment thereby reducing the time needed for the patient to take both nebulizer and OPEP treatments separately.
The personalised approach to inhaled medicine - Ensure your respiratory patients are prepared in case of emergency
Join Professor Anna Murphy as she highlights the role of spacers in optimising inhaled medication delivery for people of all ages and ensuring patients are prepared in case of emergency.
